Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 10 2021 - 8:30AM
Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the
"Company") (NASDAQ:DYAI), a global biotechnology company focused on
further improving, applying, and deploying its proprietary C1-cell
protein production platform to accelerate development, lower
production costs and improve the performance of biologic vaccines
and therapeutics at flexible commercial scales, today announced
that the Company’s management will be attending and presenting at
the following upcoming virtual investor event:
Event DetailsPresenter: Mark
Emalfarb, CEO
Date: Monday, September 13, 2021Time: 7:00 AM
Eastern Time – Presentation will also be available on demand during
the conference September 13 - 15, 2021Event Link:
https://hcwevents.com/annualconference/
Dyadic management will be available during the
event for one-one-one meetings. Interested investors may request a
one-on-one meeting at hzosiak@dyadic.com or contact
Dyadic at (561) 743-8333.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical protein production
platform based on the fungus Thermothelomyces heterothallica
(formerly Myceliophthora thermophila), named C1. The C1
microorganism, which enables the development and large-scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
scales. Dyadic is using the C1 technology and other technologies to
conduct research, development and commercial activities for the
development and manufacturing of human and animal vaccines and
drugs, such as virus like particles (VLPs) and antigens, monoclonal
antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars
and/or biobetters, and other therapeutic proteins. Certain other
research activities are ongoing which include the exploration of
using C1 to develop and produce certain metabolites and other
biologic products. Dyadic pursues research and development
collaborations, licensing arrangements and other commercial
opportunities with its partners and collaborators to leverage the
value and benefits of these technologies in development and
manufacture of biopharmaceuticals. In particular, as the aging
population grows in developed and undeveloped countries, Dyadic
believes the C1 technology may help bring biologic vaccines, drugs
and other biologic products to market faster, in greater volumes,
at lower cost, and with new properties to drug developers and
manufacturers, and improve access and cost to patients and the
healthcare system, but most importantly save lives.
Please visit Dyadic’s website at http://www.dyadic.com/ for
additional information, including details regarding Dyadic’s plans
for its biopharmaceutical business.
Contact:
Dyadic International, Inc.Mark Emalfarb,
CEOPhone: (561) 743-8333Email: memalfarb@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024